Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon
Deal with BC Partners aims to capitalise on rising demand for off-patent versions of complex drugs
Full Article
Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon
FT.com
0 shares
1 views